 Steven Ahrendt
Concepts (251)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peritoneal Neoplasms | 23 | 2025 | 102 | 2.920 |
Why?
| | Hyperthermia, Induced | 21 | 2024 | 122 | 2.130 |
Why?
| | Cytoreduction Surgical Procedures | 15 | 2025 | 65 | 1.920 |
Why?
| | Pancreatic Neoplasms | 16 | 2024 | 924 | 1.450 |
Why?
| | Appendiceal Neoplasms | 13 | 2019 | 28 | 1.430 |
Why?
| | Pancreatectomy | 9 | 2024 | 267 | 1.040 |
Why?
| | Chemotherapy, Cancer, Regional Perfusion | 16 | 2024 | 29 | 0.950 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 18 | 2024 | 1827 | 0.780 |
Why?
| | Carcinoma, Pancreatic Ductal | 5 | 2024 | 308 | 0.720 |
Why?
| | Adenocarcinoma, Mucinous | 7 | 2020 | 78 | 0.650 |
Why?
| | Survival Rate | 24 | 2024 | 2003 | 0.570 |
Why?
| | Neoadjuvant Therapy | 7 | 2024 | 438 | 0.520 |
Why?
| | Prognosis | 27 | 2024 | 4152 | 0.500 |
Why?
| | Hyperglycemia | 1 | 2020 | 365 | 0.480 |
Why?
| | Combined Modality Therapy | 18 | 2025 | 1252 | 0.470 |
Why?
| | Adenocarcinoma | 6 | 2024 | 911 | 0.440 |
Why?
| | Neoplasm Recurrence, Local | 7 | 2019 | 1095 | 0.430 |
Why?
| | Carcinoma, Signet Ring Cell | 4 | 2016 | 17 | 0.430 |
Why?
| | Colorectal Neoplasms | 6 | 2024 | 833 | 0.420 |
Why?
| | Stomach Neoplasms | 3 | 2024 | 118 | 0.380 |
Why?
| | Lung Neoplasms | 7 | 2019 | 2580 | 0.360 |
Why?
| | Follow-Up Studies | 21 | 2024 | 5308 | 0.350 |
Why?
| | Mesothelioma | 3 | 2016 | 46 | 0.330 |
Why?
| | Biomarkers, Tumor | 4 | 2015 | 1282 | 0.300 |
Why?
| | Neoplasm Staging | 13 | 2022 | 1416 | 0.300 |
Why?
| | Neoplasm Grading | 9 | 2015 | 312 | 0.290 |
Why?
| | Middle Aged | 39 | 2025 | 35343 | 0.280 |
Why?
| | Genes, p53 | 3 | 2003 | 68 | 0.280 |
Why?
| | Cholangitis, Sclerosing | 2 | 1999 | 57 | 0.280 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 3 | 2003 | 1133 | 0.270 |
Why?
| | Lymphatic Metastasis | 9 | 2024 | 328 | 0.270 |
Why?
| | Postoperative Complications | 7 | 2025 | 2887 | 0.270 |
Why?
| | Fluorouracil | 3 | 2024 | 210 | 0.270 |
Why?
| | Retrospective Studies | 20 | 2025 | 16740 | 0.270 |
Why?
| | Bile Duct Neoplasms | 2 | 2018 | 121 | 0.260 |
Why?
| | Prospective Studies | 19 | 2025 | 7900 | 0.260 |
Why?
| | Aged | 27 | 2024 | 25322 | 0.250 |
Why?
| | Chemotherapy, Adjuvant | 8 | 2016 | 388 | 0.250 |
Why?
| | Survival Analysis | 8 | 2016 | 1332 | 0.240 |
Why?
| | Laparoscopy | 2 | 2021 | 474 | 0.230 |
Why?
| | Smad4 Protein | 1 | 2005 | 36 | 0.230 |
Why?
| | Genes, ras | 3 | 2002 | 94 | 0.220 |
Why?
| | Mutation | 6 | 2014 | 4053 | 0.210 |
Why?
| | Male | 42 | 2025 | 71501 | 0.210 |
Why?
| | Urologic Surgical Procedures | 1 | 2025 | 118 | 0.210 |
Why?
| | Antineoplastic Agents | 4 | 2021 | 2195 | 0.210 |
Why?
| | Thymidylate Synthase | 1 | 2003 | 13 | 0.200 |
Why?
| | Armillaria | 1 | 2023 | 3 | 0.200 |
Why?
| | Coelomomyces | 1 | 2023 | 1 | 0.200 |
Why?
| | Female | 42 | 2025 | 77252 | 0.200 |
Why?
| | Anopheles | 1 | 2023 | 17 | 0.200 |
Why?
| | Lentinula | 1 | 2023 | 1 | 0.200 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2003 | 96 | 0.200 |
Why?
| | Parasites | 1 | 2023 | 44 | 0.190 |
Why?
| | Humans | 51 | 2025 | 143560 | 0.190 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2005 | 550 | 0.190 |
Why?
| | Pancreaticoduodenectomy | 2 | 2021 | 129 | 0.180 |
Why?
| | Carcinoma | 3 | 2015 | 230 | 0.180 |
Why?
| | CA-19-9 Antigen | 3 | 2022 | 30 | 0.180 |
Why?
| | Proportional Hazards Models | 6 | 2022 | 1292 | 0.170 |
Why?
| | Pancreatic Cyst | 1 | 2002 | 50 | 0.170 |
Why?
| | Nomograms | 1 | 2022 | 58 | 0.170 |
Why?
| | Body Composition | 1 | 2024 | 711 | 0.160 |
Why?
| | Cyclins | 1 | 2000 | 101 | 0.160 |
Why?
| | Cystadenoma, Serous | 1 | 2020 | 18 | 0.160 |
Why?
| | Neuroendocrine Tumors | 1 | 2002 | 112 | 0.160 |
Why?
| | Databases, Factual | 2 | 2024 | 1465 | 0.160 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2020 | 84 | 0.150 |
Why?
| | Pseudomyxoma Peritonei | 1 | 2019 | 5 | 0.150 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 1999 | 61 | 0.150 |
Why?
| | Pleural Neoplasms | 1 | 2019 | 27 | 0.150 |
Why?
| | Kaplan-Meier Estimate | 6 | 2016 | 921 | 0.140 |
Why?
| | Aged, 80 and over | 10 | 2021 | 8072 | 0.140 |
Why?
| | Cholangiocarcinoma | 1 | 1999 | 100 | 0.140 |
Why?
| | Adult | 20 | 2024 | 40012 | 0.140 |
Why?
| | Adenoma | 1 | 2020 | 221 | 0.140 |
Why?
| | Treatment Outcome | 10 | 2025 | 11365 | 0.130 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 682 | 0.130 |
Why?
| | Wearable Electronic Devices | 1 | 2018 | 61 | 0.130 |
Why?
| | Patient Compliance | 1 | 2021 | 617 | 0.130 |
Why?
| | Carcinoid Tumor | 1 | 2016 | 22 | 0.120 |
Why?
| | Sequence Analysis, DNA | 2 | 2016 | 823 | 0.120 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2016 | 75 | 0.120 |
Why?
| | Depression | 2 | 2016 | 1512 | 0.110 |
Why?
| | Bile | 1 | 1994 | 25 | 0.110 |
Why?
| | Telomerase | 1 | 1997 | 249 | 0.110 |
Why?
| | Glucose | 1 | 2020 | 1042 | 0.110 |
Why?
| | Pancreatic Fistula | 1 | 2014 | 34 | 0.110 |
Why?
| | GTP-Binding Protein alpha Subunits, Gs | 1 | 2014 | 9 | 0.110 |
Why?
| | Learning Curve | 1 | 2014 | 71 | 0.110 |
Why?
| | Age Factors | 4 | 2022 | 3328 | 0.100 |
Why?
| | Microsporidia | 1 | 2013 | 2 | 0.100 |
Why?
| | Inpatients | 1 | 2018 | 521 | 0.100 |
Why?
| | Chytridiomycota | 1 | 2013 | 28 | 0.100 |
Why?
| | Immunohistochemistry | 4 | 2016 | 1736 | 0.100 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2014 | 104 | 0.100 |
Why?
| | DNA, Fungal | 1 | 2013 | 83 | 0.100 |
Why?
| | Genome, Fungal | 1 | 2013 | 41 | 0.100 |
Why?
| | Walking | 1 | 2018 | 557 | 0.100 |
Why?
| | CA-125 Antigen | 1 | 2012 | 13 | 0.100 |
Why?
| | Cholesterol | 1 | 1994 | 404 | 0.090 |
Why?
| | Appendectomy | 1 | 2013 | 89 | 0.090 |
Why?
| | Gastrectomy | 1 | 2013 | 143 | 0.090 |
Why?
| | Patient Readmission | 1 | 2018 | 706 | 0.090 |
Why?
| | Fatigue | 1 | 2014 | 349 | 0.090 |
Why?
| | Carcinoembryonic Antigen | 2 | 2024 | 37 | 0.090 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2003 | 763 | 0.090 |
Why?
| | Genomics | 1 | 2016 | 831 | 0.090 |
Why?
| | Leucovorin | 2 | 2024 | 87 | 0.080 |
Why?
| | Predictive Value of Tests | 3 | 2014 | 2086 | 0.080 |
Why?
| | Sarcoma | 1 | 2013 | 194 | 0.080 |
Why?
| | Disease-Free Survival | 3 | 2013 | 720 | 0.080 |
Why?
| | Kidney Diseases | 1 | 2014 | 412 | 0.080 |
Why?
| | DNA Mutational Analysis | 3 | 2016 | 404 | 0.080 |
Why?
| | Registries | 1 | 2018 | 2238 | 0.080 |
Why?
| | Morbidity | 3 | 2016 | 321 | 0.080 |
Why?
| | Quality of Life | 2 | 2019 | 3080 | 0.070 |
Why?
| | Mitomycin | 3 | 2013 | 34 | 0.070 |
Why?
| | Cisplatin | 3 | 2016 | 333 | 0.070 |
Why?
| | Sex Factors | 2 | 2022 | 2092 | 0.070 |
Why?
| | Lung Diseases | 1 | 2014 | 787 | 0.070 |
Why?
| | Lymph Nodes | 2 | 2002 | 499 | 0.060 |
Why?
| | Antineoplastic Protocols | 1 | 2025 | 6 | 0.060 |
Why?
| | Neoplasm Invasiveness | 2 | 2020 | 518 | 0.060 |
Why?
| | Thymidine Phosphorylase | 1 | 2005 | 14 | 0.060 |
Why?
| | Peritoneum | 1 | 2025 | 45 | 0.060 |
Why?
| | Injections, Intraperitoneal | 2 | 2016 | 116 | 0.060 |
Why?
| | Angiogenesis Inducing Agents | 1 | 2005 | 25 | 0.060 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2005 | 50 | 0.060 |
Why?
| | Microcirculation | 1 | 2005 | 138 | 0.060 |
Why?
| | Infusions, Parenteral | 2 | 2016 | 43 | 0.060 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2005 | 217 | 0.050 |
Why?
| | Biomarkers | 2 | 2014 | 4241 | 0.050 |
Why?
| | Polymerase Chain Reaction | 3 | 2016 | 1062 | 0.050 |
Why?
| | Phylogeny | 2 | 2023 | 1008 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2014 | 1510 | 0.050 |
Why?
| | Anthropometry | 1 | 2024 | 208 | 0.050 |
Why?
| | Risk Assessment | 3 | 2016 | 3577 | 0.050 |
Why?
| | Angiogenesis Inhibitors | 1 | 2005 | 234 | 0.050 |
Why?
| | Crustacea | 1 | 2023 | 5 | 0.050 |
Why?
| | Forecasting | 1 | 2005 | 384 | 0.050 |
Why?
| | Adolescent | 6 | 2022 | 22482 | 0.050 |
Why?
| | Dideoxynucleosides | 1 | 2003 | 21 | 0.050 |
Why?
| | Gene Transfer, Horizontal | 1 | 2023 | 35 | 0.050 |
Why?
| | Agaricus | 1 | 2023 | 3 | 0.050 |
Why?
| | Pennsylvania | 2 | 2014 | 135 | 0.050 |
Why?
| | Thailand | 1 | 2023 | 17 | 0.050 |
Why?
| | Young Adult | 5 | 2022 | 13972 | 0.050 |
Why?
| | Biomass | 1 | 2023 | 115 | 0.050 |
Why?
| | Time Factors | 3 | 2025 | 7032 | 0.050 |
Why?
| | Inflammation | 1 | 2014 | 2881 | 0.050 |
Why?
| | Larva | 1 | 2023 | 239 | 0.050 |
Why?
| | Genetic Markers | 1 | 2003 | 345 | 0.050 |
Why?
| | Risk Factors | 3 | 2024 | 10644 | 0.050 |
Why?
| | Intraoperative Care | 1 | 2002 | 63 | 0.040 |
Why?
| | Biopsy, Needle | 1 | 2002 | 190 | 0.040 |
Why?
| | Plants | 1 | 2023 | 225 | 0.040 |
Why?
| | Liver Transplantation | 2 | 1999 | 814 | 0.040 |
Why?
| | Regression Analysis | 1 | 2003 | 1013 | 0.040 |
Why?
| | Obesity | 1 | 2014 | 3042 | 0.040 |
Why?
| | Tumor Burden | 1 | 2022 | 319 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2022 | 234 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2000 | 127 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2024 | 654 | 0.040 |
Why?
| | Actuarial Analysis | 1 | 1999 | 22 | 0.040 |
Why?
| | Perioperative Care | 1 | 2002 | 234 | 0.040 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 1999 | 20 | 0.040 |
Why?
| | Neoplasms | 1 | 2014 | 2804 | 0.040 |
Why?
| | France | 1 | 2018 | 40 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2003 | 1263 | 0.030 |
Why?
| | Ecosystem | 1 | 2023 | 583 | 0.030 |
Why?
| | DNA Methylation | 1 | 2003 | 667 | 0.030 |
Why?
| | Liver Neoplasms | 1 | 2024 | 758 | 0.030 |
Why?
| | Dilatation | 1 | 1998 | 71 | 0.030 |
Why?
| | Hepatectomy | 1 | 1999 | 258 | 0.030 |
Why?
| | Cause of Death | 1 | 1999 | 459 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2003 | 1487 | 0.030 |
Why?
| | Organoplatinum Compounds | 1 | 2016 | 51 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 994 | 0.030 |
Why?
| | Microdissection | 1 | 2016 | 15 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2002 | 1984 | 0.030 |
Why?
| | Linear Models | 1 | 1999 | 858 | 0.030 |
Why?
| | Postoperative Period | 1 | 2018 | 361 | 0.030 |
Why?
| | Comorbidity | 1 | 2022 | 1678 | 0.030 |
Why?
| | Transcriptome | 1 | 2023 | 1029 | 0.030 |
Why?
| | Goblet Cells | 1 | 2016 | 22 | 0.030 |
Why?
| | Microsatellite Instability | 1 | 2016 | 52 | 0.030 |
Why?
| | DNA Mismatch Repair | 1 | 2016 | 50 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 1999 | 333 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2000 | 539 | 0.030 |
Why?
| | Peritoneal Cavity | 1 | 2016 | 30 | 0.030 |
Why?
| | Camptothecin | 1 | 2016 | 123 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 2015 | 206 | 0.030 |
Why?
| | Cholelithiasis | 1 | 1994 | 37 | 0.030 |
Why?
| | Micelles | 1 | 1994 | 39 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 1 | 1999 | 361 | 0.030 |
Why?
| | Chromogranins | 1 | 2014 | 13 | 0.030 |
Why?
| | Crystallization | 1 | 1994 | 147 | 0.030 |
Why?
| | Necrosis | 1 | 2015 | 247 | 0.030 |
Why?
| | Loss of Heterozygosity | 1 | 2014 | 51 | 0.030 |
Why?
| | Preoperative Period | 1 | 2014 | 145 | 0.030 |
Why?
| | Reoperation | 1 | 2016 | 605 | 0.030 |
Why?
| | Stents | 1 | 1998 | 543 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 431 | 0.030 |
Why?
| | Mortality | 1 | 2016 | 364 | 0.020 |
Why?
| | Cell Wall | 1 | 2013 | 61 | 0.020 |
Why?
| | Odds Ratio | 1 | 2016 | 1060 | 0.020 |
Why?
| | ras Proteins | 1 | 2014 | 146 | 0.020 |
Why?
| | Sarcoma, Synovial | 1 | 2013 | 22 | 0.020 |
Why?
| | Phospholipids | 1 | 1994 | 212 | 0.020 |
Why?
| | Leiomyosarcoma | 1 | 2013 | 29 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2014 | 527 | 0.020 |
Why?
| | Liposarcoma | 1 | 2013 | 30 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 258 | 0.020 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2013 | 39 | 0.020 |
Why?
| | Omentum | 1 | 2012 | 9 | 0.020 |
Why?
| | Precision Medicine | 1 | 2016 | 444 | 0.020 |
Why?
| | Incidence | 1 | 1999 | 2844 | 0.020 |
Why?
| | Splenectomy | 1 | 2012 | 61 | 0.020 |
Why?
| | Length of Stay | 1 | 1998 | 1279 | 0.020 |
Why?
| | DNA Damage | 1 | 2015 | 446 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2014 | 418 | 0.020 |
Why?
| | United States | 2 | 2021 | 15554 | 0.020 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2012 | 135 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2002 | 2779 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2014 | 626 | 0.020 |
Why?
| | Doxorubicin | 1 | 2013 | 381 | 0.020 |
Why?
| | Biopsy | 1 | 2014 | 1083 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2013 | 1314 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2014 | 781 | 0.020 |
Why?
| | Evolution, Molecular | 1 | 2013 | 507 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2014 | 1226 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2013 | 2942 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2016 | 2020 | 0.020 |
Why?
| | Child | 2 | 1999 | 22725 | 0.020 |
Why?
| | Case-Control Studies | 1 | 1994 | 3625 | 0.020 |
Why?
| | Body Mass Index | 1 | 2014 | 2430 | 0.010 |
Why?
| | O(6)-Methylguanine-DNA Methyltransferase | 1 | 2003 | 6 | 0.010 |
Why?
| | Sulfites | 1 | 2003 | 9 | 0.010 |
Why?
| | Glutathione S-Transferase pi | 1 | 2003 | 10 | 0.010 |
Why?
| | Adenomatous Polyposis Coli Protein | 1 | 2003 | 21 | 0.010 |
Why?
| | Glutathione Transferase | 1 | 2003 | 99 | 0.010 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2003 | 90 | 0.010 |
Why?
| | Isoenzymes | 1 | 2003 | 299 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2014 | 6025 | 0.010 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2001 | 69 | 0.010 |
Why?
| | Animals | 1 | 2023 | 38010 | 0.010 |
Why?
| | Codon | 1 | 2001 | 92 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2003 | 1511 | 0.010 |
Why?
| | DNA | 1 | 2003 | 1457 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2001 | 3380 | 0.010 |
Why?
|
|
Ahrendt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|